Posts by Mike Mooney
Advancing Hope: AFTD Helps Organize C9orf72 Prevention Trial Workshop
A recent publication, Design considerations for C9orf72 disease prevention trials, arose from a two-day workshop that was led by Adam Boxer, MD, PhD, (UCSF) and Michael Benatar, MD, PhD, (University…
Read MoreDear Helpline: What Comes After an FTD Diagnosis?
When a doctor first says the words frontotemporal degeneration (FTD), everything changes. Some describe it as feeling like the ground drops out from under them — fear, grief, and endless…
Read MorePartners in FTD Care: Genetic FTD Trials Update – Approaching a Phase 3 Milestone
The FTD research landscape is on the verge of major developments. For the first time, a Phase 3 trial has been completed for a potentially disease-modifying treatment for genetic FTD,…
Read MorePeople at Potential Risk of Developing FTD Share Views on Effects of Predictive Biomarker Testing
People at risk, or potentially at risk, of developing FTD from a genetic mutation shared their perspectives on the potential effects the results of predictive biomarker testing would have on…
Read MoreAdvocacy Update: FTD Research at NIH Highlighted in FY26 LHHS Appropriations Reports
AFTD is excited to share that congressional reports for the Fiscal Year (FY) 2026 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bills in the Senate and…
Read MoreGroup of MAPT Gene Variations Linked to Greater Risk of Pick’s Disease Pathology, Study Finds
A study published in The Lancet Neurology found that a MAPT genetic variant is associated with an increased risk of an FTD tau pathology called Pick’s disease. This MAPT gene…
Read More
